Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer

Hitoshi Kusaba, Taito Esaki, Kitaro Futami, Sinnosuke Tanaka, Hiromitsu Fujishima, Kenji Mitsugi, Kenji Sakai, hiroshi ariyama, Risa Tanaka, Naoko Kinugawa, Takashi Ueki, Rhuichi Mibu, Eishi Baba, Shuji Nakano, Koichi Akashi

研究成果: ジャーナルへの寄稿記事

6 引用 (Scopus)

抄録

The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan is expected to be a promising regimen for advanced colorectal cancer. This study was performed to determine the maximum tolerated dose (MTD) and recommended dose (RD) of irinotecan combined with S-1 in a 3-week cycle regimen and to observe the safety and efficacy for patients with previously untreated advanced colorectal cancer. Eighty milligrams per m2 of S-1 was given orally for 14 consecutive days and escalated doses of irinotecan were administered on days 1 and 8 every 3 weeks in the phase I trial. Forty patients were treated at the RD during the phase II trial. Forty-three patients were enrolled between February 2005 and March 2007. The dose-limiting toxicity was diarrhea and abdominal pain. The MTD of irinotecan was 100 mg/m2 and the RD was determined to be 80 mg/m2 of irinotecan combined with 80 mg/m2 of S-1. The phase II trial showed that 22 of 40 patients achieved a complete or partial response and eight had stable disease. The overall response rate was 55.0%. The median progression-free survival time and median survival time were 6.7 and 21 months, respectively. There were no treatment-related deaths. The main toxicities were leukopenia, neutropenia, anorexia and diarrhea. This study suggests the combination of irinotecan and S-1 repeated every 3 weeks is tolerable and effective for patients with previously untreated advanced colorectal cancer. (Cancer Sci 2010; 101: 2591-2595)

元の言語英語
ページ(範囲)2591-2595
ページ数5
ジャーナルCancer Science
101
発行部数12
DOI
出版物ステータス出版済み - 12 1 2010

Fingerprint

irinotecan
Colorectal Neoplasms
Maximum Tolerated Dose
Diarrhea
Leukopenia
Anorexia
Patient Safety
Neutropenia
Abdominal Pain
Disease-Free Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer. / Kusaba, Hitoshi; Esaki, Taito; Futami, Kitaro; Tanaka, Sinnosuke; Fujishima, Hiromitsu; Mitsugi, Kenji; Sakai, Kenji; ariyama, hiroshi; Tanaka, Risa; Kinugawa, Naoko; Ueki, Takashi; Mibu, Rhuichi; Baba, Eishi; Nakano, Shuji; Akashi, Koichi.

:: Cancer Science, 巻 101, 番号 12, 01.12.2010, p. 2591-2595.

研究成果: ジャーナルへの寄稿記事

Kusaba, H, Esaki, T, Futami, K, Tanaka, S, Fujishima, H, Mitsugi, K, Sakai, K, ariyama, H, Tanaka, R, Kinugawa, N, Ueki, T, Mibu, R, Baba, E, Nakano, S & Akashi, K 2010, 'Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer', Cancer Science, 巻. 101, 番号 12, pp. 2591-2595. https://doi.org/10.1111/j.1349-7006.2010.01728.x
Kusaba, Hitoshi ; Esaki, Taito ; Futami, Kitaro ; Tanaka, Sinnosuke ; Fujishima, Hiromitsu ; Mitsugi, Kenji ; Sakai, Kenji ; ariyama, hiroshi ; Tanaka, Risa ; Kinugawa, Naoko ; Ueki, Takashi ; Mibu, Rhuichi ; Baba, Eishi ; Nakano, Shuji ; Akashi, Koichi. / Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer. :: Cancer Science. 2010 ; 巻 101, 番号 12. pp. 2591-2595.
@article{4cbc08ddab4a4279a47a961661eee97f,
title = "Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer",
abstract = "The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan is expected to be a promising regimen for advanced colorectal cancer. This study was performed to determine the maximum tolerated dose (MTD) and recommended dose (RD) of irinotecan combined with S-1 in a 3-week cycle regimen and to observe the safety and efficacy for patients with previously untreated advanced colorectal cancer. Eighty milligrams per m2 of S-1 was given orally for 14 consecutive days and escalated doses of irinotecan were administered on days 1 and 8 every 3 weeks in the phase I trial. Forty patients were treated at the RD during the phase II trial. Forty-three patients were enrolled between February 2005 and March 2007. The dose-limiting toxicity was diarrhea and abdominal pain. The MTD of irinotecan was 100 mg/m2 and the RD was determined to be 80 mg/m2 of irinotecan combined with 80 mg/m2 of S-1. The phase II trial showed that 22 of 40 patients achieved a complete or partial response and eight had stable disease. The overall response rate was 55.0{\%}. The median progression-free survival time and median survival time were 6.7 and 21 months, respectively. There were no treatment-related deaths. The main toxicities were leukopenia, neutropenia, anorexia and diarrhea. This study suggests the combination of irinotecan and S-1 repeated every 3 weeks is tolerable and effective for patients with previously untreated advanced colorectal cancer. (Cancer Sci 2010; 101: 2591-2595)",
author = "Hitoshi Kusaba and Taito Esaki and Kitaro Futami and Sinnosuke Tanaka and Hiromitsu Fujishima and Kenji Mitsugi and Kenji Sakai and hiroshi ariyama and Risa Tanaka and Naoko Kinugawa and Takashi Ueki and Rhuichi Mibu and Eishi Baba and Shuji Nakano and Koichi Akashi",
year = "2010",
month = "12",
day = "1",
doi = "10.1111/j.1349-7006.2010.01728.x",
language = "English",
volume = "101",
pages = "2591--2595",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer

AU - Kusaba, Hitoshi

AU - Esaki, Taito

AU - Futami, Kitaro

AU - Tanaka, Sinnosuke

AU - Fujishima, Hiromitsu

AU - Mitsugi, Kenji

AU - Sakai, Kenji

AU - ariyama, hiroshi

AU - Tanaka, Risa

AU - Kinugawa, Naoko

AU - Ueki, Takashi

AU - Mibu, Rhuichi

AU - Baba, Eishi

AU - Nakano, Shuji

AU - Akashi, Koichi

PY - 2010/12/1

Y1 - 2010/12/1

N2 - The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan is expected to be a promising regimen for advanced colorectal cancer. This study was performed to determine the maximum tolerated dose (MTD) and recommended dose (RD) of irinotecan combined with S-1 in a 3-week cycle regimen and to observe the safety and efficacy for patients with previously untreated advanced colorectal cancer. Eighty milligrams per m2 of S-1 was given orally for 14 consecutive days and escalated doses of irinotecan were administered on days 1 and 8 every 3 weeks in the phase I trial. Forty patients were treated at the RD during the phase II trial. Forty-three patients were enrolled between February 2005 and March 2007. The dose-limiting toxicity was diarrhea and abdominal pain. The MTD of irinotecan was 100 mg/m2 and the RD was determined to be 80 mg/m2 of irinotecan combined with 80 mg/m2 of S-1. The phase II trial showed that 22 of 40 patients achieved a complete or partial response and eight had stable disease. The overall response rate was 55.0%. The median progression-free survival time and median survival time were 6.7 and 21 months, respectively. There were no treatment-related deaths. The main toxicities were leukopenia, neutropenia, anorexia and diarrhea. This study suggests the combination of irinotecan and S-1 repeated every 3 weeks is tolerable and effective for patients with previously untreated advanced colorectal cancer. (Cancer Sci 2010; 101: 2591-2595)

AB - The combination of an oral fluoropyrimidine derivative, S-1, and irinotecan is expected to be a promising regimen for advanced colorectal cancer. This study was performed to determine the maximum tolerated dose (MTD) and recommended dose (RD) of irinotecan combined with S-1 in a 3-week cycle regimen and to observe the safety and efficacy for patients with previously untreated advanced colorectal cancer. Eighty milligrams per m2 of S-1 was given orally for 14 consecutive days and escalated doses of irinotecan were administered on days 1 and 8 every 3 weeks in the phase I trial. Forty patients were treated at the RD during the phase II trial. Forty-three patients were enrolled between February 2005 and March 2007. The dose-limiting toxicity was diarrhea and abdominal pain. The MTD of irinotecan was 100 mg/m2 and the RD was determined to be 80 mg/m2 of irinotecan combined with 80 mg/m2 of S-1. The phase II trial showed that 22 of 40 patients achieved a complete or partial response and eight had stable disease. The overall response rate was 55.0%. The median progression-free survival time and median survival time were 6.7 and 21 months, respectively. There were no treatment-related deaths. The main toxicities were leukopenia, neutropenia, anorexia and diarrhea. This study suggests the combination of irinotecan and S-1 repeated every 3 weeks is tolerable and effective for patients with previously untreated advanced colorectal cancer. (Cancer Sci 2010; 101: 2591-2595)

UR - http://www.scopus.com/inward/record.url?scp=78449310290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78449310290&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2010.01728.x

DO - 10.1111/j.1349-7006.2010.01728.x

M3 - Article

VL - 101

SP - 2591

EP - 2595

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 12

ER -